Viriom

Viriom is a clinical-stage biotech company advancing a pipeline of antiviral therapies, primarily for HIV, with a mission to ensure broad global access. Its lead asset, Elpida® (elsulfavirine), is an NNRTI approved in Russia and Eurasian markets, with development ongoing for weekly oral and long-acting injectable formulations. The company is also expanding its focus to include treatments for SARS-CoV-2, influenza, Hepatitis B/C, and solid tumors, supported by a leadership team with deep virology and drug development expertise.

Platform focused on developing antiviral therapies and formulations designed to overcome drug resistance. Core strategies include using drug combinations (e.g., fixed-dose combinations), developing less frequent dosing regimens (weekly oral, long-acting injectables), and creating therapies resistant to viral mutation.

In HIV, Viriom faces intense competition from large pharmaceutical companies (GSK/ViiV, Gilead, Janssen) with dominant market share, extensive portfolios, and their own long-acting injectables. In COVID-19, the favipiravir program competes in a crowded, evolving market with newer antivirals like Paxlovid. Differentiation hinges on Viriom's unique formulations, focus on resistance, and access-driven pricing.